BIODESIX INC

BDSX11 Dec 2024
Healthcare
$1.3
-0.04 (-3.79%)
Lowest Today
$1.26
Highest Today
$1.3
Today’s Open
$1.3
Prev. Close
$1.32
52 Week High
$2.21
52 Week Low
$1.11
To Invest in BIODESIX INC

BIODESIX INC

Healthcare
BDSX11 Dec 2024
-0.04 (-3.79%)
1M
3M
6M
1Y
5Y
Low
$1.26
Day’s Range
High
$1.3
1.26
52 Week Low
$1.11
52-Week Range
52 Week High
$2.21
1.11
1 Day
-
1 Week
-1.85%
1 month return
-6.38%
3 month return
-26.25%
6 month return
-13.72%
1 Year return
-16.45%
3 Years return
-72.21%
5 Years return
-
10 Years return
-
Institutional Holdings
Telemark Asset Management, LLC
5.69
AIGH Capital Management, LLC
3.9
Birchview Capital, LP
3.81
Farallon Capital Management, L.L.C.
3.19
Sio Capital Management, LLC
2.98
Soleus Capital Management, L.P.
2.78
Opaleye Management Inc
2.62

Market Status

Fundamentals
Market Cap
197.84 mln
PB Ratio
7.05
PE Ratio
0
Enterprise Value
226.93 mln
Total Assets
99.1 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Organisation
BIODESIX INC
Employees
217
Industry
Diagnostics & Research
CEO
Mr. Scott  Hutton
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step